Changes to drug coverage in Medicare Part D plans, a law that protected Big Tech is now being used against them, and more

More diversity with the integrated research model

In Part 1 of this video interview, Ashley Moultrie, CCRP, Senior Director, DEI & Community Engagement, Javara highlights how IROs bring care directly to patients and make them feel more comfortable.

Study shows changes in drug coverage in Medicare Part D plans

Kylie Stengel of Avalere discusses regional changes to drug lists and utilization management in Medicare Part D drug plans.

How a law that protects big tech companies is now being used against them

A Massachusetts professor has filed a lawsuit against Meta, relying on a novel interpretation of Section 230 of the law, which is best known for protecting social media companies from liability.

Pfizer and BioNTech receive US FDA approval and authorization for COVID-19 vaccine adapted from Omicron KP.2

Pfizer Inc. and BioNTech SE announced that the U.S. Food and Drug Administration approved the supplemental biologics authorization application for individuals 12 years of age and older (COMIRNATY® (COVID-19 vaccine, mRNA)) and granted an emergency use authorization for individuals 6 months to 11 years of age (Pfizer-BioNTech COVID-19 vaccine) for the companies' Omicron KP.2-adapted COVID-19 vaccine in the 2024-2025 formulary. This season's vaccine is intended for most individuals 5 years of age and older as a single dose. Individuals 5 years of age and older with certain types of immunodeficiency who have been previously vaccinated with Pfizer and BioNTech COVID-19 vaccines or children under 5 years of age who have not completed three doses of previous formularies of a COVID-19 vaccine may be eligible to receive additional doses.

Mike Christel on LinkedIn

I got a lot of chatting about Ken Keller, a veteran biopharma executive. He talked about his journey from sales rep to CEO of Daiichi Sankyo US—and the launch of next-generation ADCs that will change the future of cancer treatment. “In oncology, we're not in the business of just putting another drug on the market. In today's world, that doesn't work. Every decision we make is about what we can do to improve the standard of care,” Keller told me for a profile in Pharmaceutical Executive. Check it out if you have a few minutes.

Do you have news you would like us to share in Pharma Pulse? Contact Social Media Editor Miranda Schmalfuhs